Skip to main content

RAS Dialogue

Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.

    • Alternative cells-of-origin influence the heterogeneity of KRAS-mutant lung adenocarcinoma
      , by Sarah Best and Kate Sutherland

      The biology of lung cancers driven by mutant KRAS is substantially influenced by the particular cell type in which the KRAS mutation arose. Understanding how the cell of origin and its surroundings react to mutant KRAS suggest therapeutic approaches.

      Continue Reading >

    • The RASopathies Network
      , by Lisa Schoyer and Beth Stronach

      RASopathies are neurodevelopmental genetic syndromes caused by germline mutations in RAS pathway genes that result in increased MAPK signaling. The RASopathies Network provides an umbrella organization to connect affected families with researchers.

      Continue Reading >

    • Intravenous High-Dose Vitamin C in Cancer Therapy
      , by Lewis Cantley and Jihye Yun

      Pharmacologic levels of vitamin C in plasma can only be achieved by intravenous administration. Vitamin C undermines RAS-mutant cells’ reliance on upregulation of glycolysis and antioxidant activities to support their cancer lifestyle.

      Continue Reading >

    • Taking RAS Research to Space
      , by Albert Chan

      High-quality crystal structures of RAS are essential for developing new drugs for this difficult target. Crystals of RAS protein grown on the International Space Station had improved qualities compared to those grown in earth gravity.

      Continue Reading >

    • The Role of Mitochondrial Dynamics in Ras-driven Cancers
      , by David Kashatus

      Mitochondria are dynamic structures that respond to the metabolic needs of cells. The altered metabolism of cells driven by oncogenic KRAS genes results in mitochondrial fission. Blocking mitochondrial fission limits transformation and tumor growth.

      Continue Reading >